Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
1000 participants
INTERVENTIONAL
2021-04-21
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Helping In-patients to Quit Smoking by Understanding Their Risk Perception, Behavior, and Attitudes Related to Smoking
NCT02866760
Epidemiology & Intervention Research for Tobacco Control
NCT00076921
Promoting Smoking Cessation in Campus
NCT05777005
A Joint Real-World Study of Digital Smoking Cessation Interventions
NCT05996029
Chinese Community Smoking Cessation Project
NCT00139516
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
comprehensive smoking cessation intervention group
Early health warning intervention combined with brief smoking cessation intervention Early health warning intervention is to tell the subjects that smoking leads to the rapid decline of their lung function, and they are at the high risk of developing COPD
early health warning intervention
early health warning intervention is to tell the subjects that smoking leads to the rapid decline of their lung function, and they are at the high risk of developing COPD.
brief smoking cessation intervention group
brief smoking cessation intervention only
early health warning intervention
early health warning intervention is to tell the subjects that smoking leads to the rapid decline of their lung function, and they are at the high risk of developing COPD.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
early health warning intervention
early health warning intervention is to tell the subjects that smoking leads to the rapid decline of their lung function, and they are at the high risk of developing COPD.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. FEV1/FVC\>70% after inhaled bronchodilator
3. current smoker (≥ 10 pack-years)
4. rate of FEV1 decline \>30ml/y
5. lived in a community for more than 1 years and has no plans to move out in the next 4 years
Exclusion Criteria
2. history of lobectomy and / or lung transplantation;
3. predicted life expectancy less than 3 years;
4. history of severe psychiatric illnesses, mental disorders, neurological disorders, malignant tumors, chronic liver disease, heart failure, autoimmune diseases, chronic kidney disease;
5. Alcoholism, drug abuse or abuse of toxic solvents;
6. Cannot finish long term follow-up or poor compliance;
7. Do not provide consent
40 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Second Hospital of Hebei Medical University
OTHER
Henan Provincial People's Hospital
OTHER
Second Hospital of Jilin University
OTHER
First Affiliated Hospital Xi'an Jiaotong University
OTHER
Shandong Provincial Hospital
OTHER_GOV
Shanxi Bethune Hospital
OTHER
Tianjin Medical University General Hospital
OTHER
The Affiliated Hospital of Inner Mongolia Medical University
OTHER
The First Hospital of Qinhuangdao
OTHER_GOV
Peking University First Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University First Hospital
Beijing, Beijing Municipality, China
The Second Hospital of Jilin University
Ch’ang-ch’un, , China
The Affiliated Hospital of Inner Mongolia Medical University
Hohhot, , China
Shandong Provincial Hospital Affiliated to Shandong University
Jing'an, , China
The First Hospital of Qinhuangdao
Qinhuangdao, , China
The Second Hospital of Hebei Medical University
Shijia Zhuang, , China
Shanxi Bethune Hospital
Taiyuan, , China
Tianjin Medical University General Hospital
Tianjin, , China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, , China
Henan Provincial People's Hospita
Zhenzhou, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017YFC2019-255
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.